Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00775645 · ClinicalTrials.gov registry record · Phase 3
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 437
- Enrollment target
NCT00775645 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 437 participants.
The verdict
NCT00775645, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 437 participants
- Enrollment target
Study Summary
RATIONALE: Acetyl-L-carnitine may prevent or lessen neuropathy caused by chemotherapy. It is not yet known whether acetyl-L-carnitine is more effective than a placebo in preventing neuropathy caused by chemotherapy. PURPOSE: This randomized phase III trial is studying acetyl-L-carnitine to see how well it works compared with a placebo in preventing neuropathy in women with stage I, stage II, or stage III breast cancer undergoing chemotherapy.
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT acetyl-L-carnitine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 437 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00775645
The ClinicalTrials.gov registry entry for NCT00775645 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 437 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00775645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00775645 about?
NCT00775645 is a clinical study titled "S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo". RATIONALE: Acetyl-L-carnitine may prevent or lessen neuropathy caused by chemotherapy. It is not yet known whether acetyl-L-carnitine is more effective than a placebo in preventing neuropathy caused by chemotherapy. PURPOSE: This randomized phase III trial is studying acetyl-L-carnitine to see how ...
What is the current status of trial NCT00775645?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 437 participants. The study started on 2009-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00775645?
The interventions under investigation include: placebo (OTHER), acetyl-L-carnitine hydrochloride (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00775645?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.